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and higher QALYs. The results were robust to sensitivity analy-
ses. CONCLUSIONS: ETV is a dominant treatment option
across all populations in the treatment of patients with CHB,
compared to LVD and ADV. The results clearly suggest that sup-
pressing VL is economically attractive.
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OBJECTIVES: The risk of HIV, HBV and HCV transmission by
blood transfusion in sub Saharan Africa is (very) high compared
to the developed world. In this economic evaluation the cost-
effectiveness of interventions (donor management, quality of
testing, administration and additional tests) improving blood
transfusion safety is explored. METHODS: The residual risks of
HIV, HBV and HCV transmission were derived for Angola,
Benin, Botswana, Côte d’Ivoire, Ethiopia, Kenya, Mozambique,
Namibia, Rwanda, Uganda and Zambia from the Global Data-
base on Blood Safety (GDBS; WHO, 2004). Cost-effectiveness
ratios of the scenarios were determined by using a decision tree
combined with a Markov-model. Health gains and costs were
discounted by 3%. RESULTS: The CURRENT (current status)
scenario is cost-saving compared to the NONE (no screening, no
donor management) scenario, averting 2.0 million Disability
Adjusted Life Years (DALYs) and saving US$ 82 million annu-
ally. Over 94,000 new HIV infections are averted and 27,674
and 3360 new HBV and HCV infections respectively. Improving
the blood transfusion services from the CURRENT to the BEST
(100% screening, no errors) scenario shows a cost-effectiveness
ratio of 56.24 US$/DALY averted. With this step 2792 new HIV
infections are averted and 1723 and 1622 new HBV and HCV
infections respectively. In addition to the BEST scenario, HIV
p24 and HCV-antigen testing would avert 19 DALYs at annual
net costs of US$ 1.2 million (63,957 US$/DALY averted).
Extending the BEST scenario with single donation multiplex
NAT averts 60 DALYs at annual net costs of US$ 9.7 million
(161,051 US$/DALY averted). CONCLUSIONS: The current
level of blood transfusion safety provided in the included coun-
tries is cost-saving. However, maximizing the effects of donor
management and screening (coverage and errors) shows a favor-
able cost-effectiveness ratio. Introducing additional tests along-
side antibody testing is associated with high costs and limited
reduction of transmission risks.
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OBJECTIVE: The AIDS Pegasys Ribavirin International Coin-
fection Trial (APRICOT) demonstrated the efﬁcacy and safety of
peginterferon alfa-2a plus ribavirin (RBV) and interferon alfa plus
ribavirin (IFN/RBV) in patients co-infected with HIV-HCV.
However, the cost-effectiveness of treating CHC with peginter-
feron alfa-2a/RBV in this patient population has not assessed from
the Spanish National Health care System (NHS) perspective. The
objective was to establish the clinical prognosis, costs and cost-
effectiveness of peginterferon alfa-2a (180 mcg/week) plus RBV
versus IFN (3 million IU, three times a week) plus RBV, in patients
with HIV-HCV co-infection from a Spanish national health care
system (NHS) perspective. METHODS: A Markov model was
developed to simulate the disease progression of 40-year old
patients with HIV-HCV co-infection. Fibrosis progresión rates
were obtained from published studies. Efﬁcacy, in terms of sus-
tained virological response (SVR), for peginterferon alfa-2a plus
RBV and IFN/RBV in patients with genotype 1, genotypes 2/3
and genotypes 1/2/3 was obtained from APRICOT. Transition
probabilities and quality of life estimates were obtained from pub-
lished literature. Unit costs were obtained from a Spanish data-
base. Cost and outcomes were discounted by 3.5% annually.
RESULTS: In genotype 1 patients, peginterferon alfa-2a plus RBV
compared with IFN/RBV increases patientxs life expectancy by
1.27 years (0.77 quality-adjusted life years (QALYs)), yielding an
incremental cost-effectiveness ratio (ICER) of €3,677/life year
gained (LYG) (€6077/QALY gained). In genotypes 2/3 patients,
peginterferon alfa-2a plus ribavirin increases life expectancy by
4.63 years (2.33 QALYs), yielding an ICER of €569/LYG
(€1130/QALY gained). In genotypes 1/2/3 patients, the ICER is
€1487/LYG (€2762/QALY gained). CONCLUSIONS: From 
the Spanish NHS perspective, peginterferon alfa-2a (40KD)
(PEGASYS®) plus ribavirin (COPEGUS®) in patients with HIV-
HCV co-infection is a cost-effective treatment option, regardless
of HCV genotype.
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Chronic Hepatitis B (CHB) is caused by chronic infection with
Hepatitis B Virus (HBV) and represents a major global health
problem. Traditional CHB treatments are lamivudine (LAM) and
interferon alfa-2a (IFN). Peginterferon alfa-2a (PEG) has been
recently approved for the treatment of CHB disease. OBJEC-
TIVES: To assess the economic and clinical impact of the use of
peginterferon alfa-2a (40KD) versus LAM for the treatment of
HBeAg-negative CHB and versus IFN for the treatment of
HBeAg-positive CHB disease in Italy. METHODS: The CHB
disease course was simulated with the use of a Markov model.
The simulation was prolonged over a cohort’s lifetime. Com-
parative evaluation of PEG vs. LAM was based on a recent phase
III clinical trial in HBeAg-negative CHB. Comparative evalua-
tion of PEG vs. IFN was based on a phase II clinical trial com-
paring the two treatments in HBeAg-positive CHB. Considered
scenarios were: 48-week PEG vs LAM treatment; 48-week PEG
vs 4-year LAM; 24-week PEG vs. IFN. Clinical outcomes mea-
sured were average life years gained (LYs) and quality-adjusted
life years (QALYs). Direct costs were considered and valued
according to current Italian national prices, tariffs and published
literature. Deterministic and probabilistic sensitivity analyses
were performed and acceptability curves generated. Costs and
outcomes were discounted at a 3.5% annual rate. RESULTS:
0.82, 0.68, and 0.26 discounted QALYs per patient are gained
with PEG vs 48-week LAM, 4-year LAM and IFN, respectively.
Discounted incremental costs per patient are €7021, €5725, and
€2304. Corresponding cost-effectiveness and cost-utility ratios
are €9440/LY and €8603/QALY, €9218/LY and €8368/QALY,
